What is hepatocellular carcinoma interventional therapy? As we all know, hepatocellular carcinoma interventional therapy is a widely used treatment in the treatment of hepatocellular carcinoma. In China, about more than 70% of liver cancer patients have received interventional treatment at various stages of tumor. Interventional therapy uses a thin catheter selectively or super-selectively inserted into the blood supply artery of liver tumor, through which appropriate amount of chemotherapeutic drugs and embolic agents are injected to cut off the blood supply and nutrition of the tumor, causing ischemia and necrosis to occur. Since 1978, interventional treatment for hepatocellular carcinoma has been very widely used and has become the main treatment strategy for patients with intermediate to advanced hepatocellular carcinoma that cannot be surgically resected, which can control tumor progression and prolong survival. Traditional hepatic artery chemoembolization–transfemoral artery access The traditional way is to puncture and cannulate through the femoral artery in the leg (groin) to the hepatic artery, inject chemotherapeutic drugs and embolic agents at the tumor vessels to block the tumor vessels and induce tumor necrosis. The femoral artery has a thick diameter and a straight path, so the cannula can be easily fed into the catheter to reach the target vessels in all parts of the body, which is the most commonly used and easy to operate vascular access. Because the femoral artery puncture site is located in the hip joint, where mobility is high, and the pressure in the femoral artery is high, the patient needs to undergo femoral artery compression for more than 8 hours after the intervention and remains bedridden, which makes it difficult for the patient to eat and defecate after the procedure. In addition, complications such as puncture site hematoma and pseudoaneurysm may occur with femoral artery access interventions, and in severe cases, surgical treatment is required to suture the puncture site that failed to close. In patients at high risk for prior venous thrombosis, postoperative bed rest may promote thrombosis and even serious complications such as pulmonary embolism. In contrast, for patients using anticoagulant/antiplatelet drugs preoperatively, a period of preoperative drug withdrawal and heparin bridging therapy is required to avoid bleeding at the surgical site, prolonging the patient’s hospital stay. Emerging interventional modality – transradial (manual) access The radial artery was first chosen by Prof. Kiemeneij for coronary intervention in 1992 with success. Since then, radial access vascular intervention has become an important complement to the femoral access technique and has been widely used in cardiac interventions. In recent years, peripheral vascular (other than cardiovascular) interventions via radial artery access have been gradually carried out worldwide. The Department of Hepatology and Oncology of Zhongshan Hospital has carried out hepatocellular carcinoma intervention via radial artery access at an early stage in China, and has completed more than 600 cases of TACE via radial artery access so far, accumulating rich experience in surgical operation. Compared with the trans-femoral artery approach, the transradial artery approach has the following advantages: 1. no postoperative braking and compression of the legs are needed, and only a special wrist compressor is needed to compress the radial artery puncture site for about 4 hours. 2. 2.No need to be bedridden for more than 8 hours, the patient can move freely after the procedure is completed, and the comfort level has been significantly improved. 3. Complications associated with radial artery puncture are less than those associated with femoral artery puncture. 4.Since no postoperative braking is required, the risk of deep vein thrombosis/pulmonary embolism of patients is reduced. 5. The new technique of radial artery access for hepatocellular carcinoma intervention is characterized by less surgical injury, high postoperative comfort, simple nursing care and no impact on patients’ quality of life, which realizes the refinement and minimally invasive treatment of hepatocellular carcinoma intervention and fully reflects the treatment concept of accelerating patients’ postoperative recovery through improved surgical operation.